Clinical Trial Update: Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of tesmilifene (YMB1002) in combination with epirubicin and cyclophosphamide for metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Epirubicin (epirubicin)
• Tesmilifene (YMB1002) (tesmilifene)

Snippet

Sponsor: YM BioSciences | Conditions: Metastatic/Recurrent Breast Cancer | Phase 1 | Status: COMPLETED